FDA Approves Second Indication for SKYRIZI (risankizumab-rzaa) to Treat Adults with Active Psoriatic…
AbbVie announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic…
Read More...
Read More...
